FMP
NASDAQ
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
3.69 USD
-0.01 (-0.271%)
Valuation Date:
Apr 26, 2024 11:32 AM
Share Price on Valuation Date
$3.69
Stock Beta
0.191
Shares Outstanding
30174200